Hormonal therapies (MHT/HRT), evolved from WHI trials, effectively reduce VMS by 70%–90% and preserve bone density via estrogen receptor modulation, with low-dose transdermal regimens minimizing VTE and breast cancer risks per NAMS/IMS guidelines. This evidence concerns the gene ESR1 and breast cancer.